
Jan 11 (Reuters) - Beam Therapeutics Inc BEAM.O:
BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR ITS GENETIC DISEASE AND HEMATOLOGY FRANCHISES TO DRIVE EXECUTION OF LATE-STAGE CLINICAL PROGRAMS AND EXTENDS ITS OPERATING RUNWAY THROUGH COMMERCIAL TRANSITION
BEAM THERAPEUTICS INC - FDA ALIGNMENT ON ACCELERATED APPROVAL PATHWAY FOR BEAM-302
BEAM THERAPEUTICS INC - RISTO-CEL BLA SUBMISSION EXPECTED BY YEAR-END 2026
BEAM THERAPEUTICS INC - TO ANNOUNCE NEW LIVER-TARGETED PROGRAM IN H1 2026